Lazard scouting Indian deals for GSK

Last week, the chatter was that GlaxoSmithKline might buy a chunk of India's Dr. Reddy's Labs. Makes sense; GSK has been on an emerging-markets push for some time. But it appears that Glaxo is

Pfizer moves to cap retiree health benefits

In further evidence of out-of-control healthcare costs, Pfizer is joining the U.S. companies capping retiree health benefits, with the size of retiree medical subsidies determined by years of

Who's the greenest pharma of all?

Today pharma can look into the magic mirror and find who is the greenest of them all. In two separate environmental rankings, drugmakers have been weighed on the eco-scale--and in some cases, found

Teva to cut 400 Czech jobs, shut plant

Teva Pharmaceutical Industries proves that the drug industry is an equal-opportunity job-cutter. It's not just the purveyors of branded meds like Merck, Schering-Plough, Wyeth, Pfizer,

New Sanofi heart drug outpaces Lilly's Effient

Now that the cardiovascular drug market has a couple of new entries, analysts are applying their skills. Their take: Eli Lilly's clot-buster Effient has been "sluggish" out of the gate, while

Boehringer corrals Wy-Pfi animal assets

The animal-health shuffle continues. As expected, Pfizer and Wyeth are offloading some animal health assets in advance of their merger, in part to get regulatory approval for the deal. Boehringer

Glaxo to stop funding commercial CME

GlaxoSmithKline is taking another step back from the drugmaker influence game. The company won't fund commercial CME programs anymore. Instead, starting next year, it will back only medical education

Witness woes in another Neurontin trial

An expert witness for the family of a man who killed himself while on Neurontin is improperly trying to sway testimony of the dead man's doctor in an approaching trial, Pfizer says. Report

Methadone maker hits auction block

Private equity firms are circling Martindale Pharmaceuticals, the U.K.'s leading maker of methadone. Put up for sale by its U.S. parent Cardinal Health with a price of about £150 million ($242

Bidding war in the offing for Goldshield

A U.K. drugmaker could find itself in the center of a bidding war. Generics maker Goldshield Group faces a bitter takeover battle, as managers work up a counterbid to last week's £162 million

Apotex recalls lots of three drugs in Canada*

More signs of manufacturing trouble at Apotex. The generics maker is recalling lots of three drugs in Canada: Apo-Amilzide, liver cirrhosis treatment; Apo-Meloxicam, an arthritis remedy and generic

Merck CEO talks up new Merial J.V.

Merck is doing the old wink-wink, nudge-nudge on joining its animal-health forces with Sanofi-Aventis, after merging with Schering-Plough, of course. CEO Dick Clark (photo) tells the Financial Times

What does pharma have in common with Target?

When the economy is in a recession, what do consumers do? They get thrifty. So discount retailers are weathering the recession better than luxury stores, for example. And not to be outdone by Target

Researchers see pharma contraction

Researcher Business Monitor International expects the U.S. pharmaceutical market to contract at a compound annual growth rate of -0.35 percent during 2008 to 2013. The contraction is expected to

Generics firms argue rebates

Increasing the use of generic drugs in government programs to the levels that exist in nongovernment markets represents "bigger money" than the government would save by hiking the rebates paid by

Barron's picks potential M&A deals

Earlier this year, the industry saw three of the largest buyout deals in recent years (Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech). Barron's speculates that additional mega-mergers are

GSK extends emerging-markets march

Reuters reports that GlaxoSmithKline is negotiating a 5 percent stake in Indian generics maker Dr Reddy's Labs. Analysts see a match between the move and a stated Glaxo goal to build up its presence

Merck's Gardasil taken up by 37% of teen girls

A CDC study shows that, nationwide, 37 percent of teen girls received the human papilloma virus vaccine Gardasil, a mainline defense against cervical cancer. Based on a 2008 telephone survey,

M.D. pilot made off-label Pfizer rounds

A penchant for helicopters characterizes forensic psychiatrist Neil Kaye, M.D., a prominent player in the recent $2.3 billion Pfizer off-label marketing settlement. According to Bnet, high-roller

Pfizer settlement funds whistleblower program

A Florida whistleblower program has received $1 million from the state's allocation of the recent $2.3 billion federal Pfizer settlement regarding illegal marketing allegations. State Sen. Don Gaetz